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Abstract The ability of ceruloplasmin (Cp) to oxidize low-
density lipoproteins (LDL) in the presence of water-soluble
antioxidants was investigated and a reaction mechanism
proposed. Ascorbate strongly enhanced LDL oxidation, but only
after its rapid consumption. Dehydroascorbate enhanced Cp-
mediated LDL oxidation even more strongly. Lipid-soluble
antioxidants and water-soluble peroxides did not show noticeable
activation. However, loading of LDL with lipid hydroperoxides
increased the initial oxidation rate. We conclude that Cp
mediates a localized redox cycle, where reduction of Cp-Cu2+
is effected by water-soluble reductants and reoxidation by
liposoluble hydroperoxides. ß 2001 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Ceruloplasmin (Cp; Mr = 132 kDa, reviewed in [1,2]) is a
blue plasma protein (300 Wg/ml approx., 2^3 times more in the
acute phase of in£ammation) carrying about 95% of total
circulating copper. Its biological function is still not quite
clear, although a number of activities have been described,
including copper transport, oxidation of organic amines [3],
ferroxidase activity, glutathione peroxidase activity [4] and
antioxidant activity in lipid peroxidation processes [5]. Proox-
idant activity of Cp has been previously reported in several
instances, such as the oxidation of DNA [6] and low-density
lipoprotein (LDL), both by intact Cp [7], and after release of
redox-active copper either by low pH [8] (e.g. at sites of in-
£ammation) or by nitric oxide/peroxynitrite [9]. Surprisingly,
Cp has long been regarded as an exclusively antioxidant en-
zyme, because the prooxidant activity of intact Cp was over-
looked due to the copuri¢cation of a metalloproteinase in Cp
preparations, leading to cleavage of Cp and concomitant loss
of prooxidant activity [10].
The crystal structure of Cp [11] con¢rmed the presence of
six copper ions. However, Cp contains seven copper ions in
total, one of which is a prooxidant in lipid peroxidation re-
actions and can be easily removed by chelation [12].
Cp has been reported to function as and to have structural
similarities to ‘proper’ ascorbate (AscH) oxidases. In the pres-
ence of oxygen, a large excess of AscH immediately reduced
the copper sites and kept them in a reduced state [13].
The oxidation of LDL is assumed to play an important role
in the development of atherosclerosis (for a review see [14]).
However, it is still unclear how LDL can be oxidized in vivo;
the presence of high concentrations of water-soluble antioxi-
dants in plasma and endothelial lining £uid [15,16] (urate
(UA), AscH) has been shown to synergistically prevent oxi-
dation of lipoproteins under in vitro experimental conditions
[17], where initiation of LDL oxidation was induced by
free transition metal ions or reactive oxygen and nitrogen
species.
Transition metal ions are probably responsible for a large
part of the oxidized lipids and proteins found in atheroscler-
otic plaques. Indeed, copper and iron have been detected in
lesion areas in sizeable quantities [18]. However, it has been
argued that metal ions might not exist in free form, but are
bound to proteins, such as transferrin or Cp. Consistently,
ferroxidase activity, indicative of Cp, was detected in athero-
sclerotic plaques [19], besides immunohistochemical detection
of the Cp protein [20].
Here, we show that the oxidation of LDL is not merely
possible in the presence of water-soluble plasma antioxidants,
but that the e⁄cient oxidation of LDL by Cp depends on the
presence of reducing cosubstrates and we propose a mecha-
nism for lipoprotein oxidation by Cp.
2. Materials and methods
All materials were of analytical grade or better, and from Sigma or
Merck (Vienna, Austria), unless speci¢ed otherwise. AscH was from
Loba (Fischamend, Austria). Rabbit reticulocyte 15-lipoxygenase (15-
LOX) was a kind gift from Prof. Hartmut Ku«hn (Hospital Charite¤,
Berlin, Germany).
2.1. Preparation of human Cp
Cp was prepared according to [21]. After overnight dialysis against
bidistilled water, Cp was lyophilized and dissolved in phosphate-bu¡-
ered saline (PBS), aliquoted and stored at 320‡C. In accordance with
published procedures, Cp purity was checked by SDS^PAGE, show-
ing the preparation to be s 95% intact. The ratio of Cp-speci¢c and
aromatic amino acid residue absorbance, A610/A280, as another indi-
cator of purity, was always s 0.047. Cp concentrations were deter-
mined from its absorbance at 610 nm, with E1%610 = 0.68 [7].
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2.2. Preparation of LDL
LDL was prepared from pooled ethylenediamine tetraacetic acid
(EDTA) plasma of healthy volunteers of both sexes by ultracentrifu-
gation in a single-step discontinuous gradient in a Beckman NVT65
rotor, as described previously [22]. Prior to use, LDL was stored in an
evacuated glass vial under argon at 4‡C for a maximum of 2 weeks.
LDL concentration was determined from its total cholesterol content,
using the CHOD-PAP enzymatic test kit (Boehringer-Mannheim,
Germany), assuming a molar mass of LDL of 2.5 MDa and a choles-
terol content of 32.2 wt%.
2.3. LDL oxidation
Prior to oxidation of LDL, EDTA and KBr were removed by gel
¢ltration as described [23]. Unless indicated otherwise, oxidation was
performed at 37‡C by addition of a 50 WM stock solution of Cp to a
0.3 WM solution of LDL, both in PBS (160 mM NaCl, 10 mM Na-
phosphate, pH 7.4), to give a ¢nal concentration of 2.25 WM Cp. All
experiments were performed at least in duplicate.
2.4. Low-level chemiluminescence (LL-CL) measurements
LL-CL was measured in a LUCY I luminometer (Anthos Labtech
Instruments, Salzburg, Austria) equipped with a single-photon-count-
ing photomultiplier (sensitivity 300^700 nm) as described [24]. Inte-
gration time was 90 s, measurements were performed in a white mi-
croplate. LL-CL is a method for continuously monitoring lipid
peroxidation far superior to UV measurement of conjugated dienes
(giving similar results) in the presence of substances absorbing
strongly in the ultraviolet spectral range. The intensity of LL-CL is
proportional to the square of the oxidation rate [24].
2.5. Loading of LDL with K-tocopherol
LDL was loaded with K-tocopherol as described [25]. Brie£y,
EDTA plasma was incubated with ethanolic K-tocopherol (250 mM,
1% of total plasma volume) for 2 h at 37‡C under argon in the dark,
and LDL was isolated subsequently as described above.
2.6. Determination of AscH and K-tocopherol
AscH was determined according to [26] using samples stabilized
with 5% meta-phosphoric acid and detected electrochemically (Ag/
AgCl 0.6 V, HP1049A detector). K-Tocopherol was determined by
HPLC and £uorescence detection after extraction of LDL, as de-
scribed [27].
3. Results
3.1. Activation of Cp by AscH
LL-CL was monitored during Cp-mediated LDL oxidation
in the presence of AscH (2.25 WM Cp, 0.3 WM LDL, 0^100
WM AscH); similar results were obtained by measuring con-
jugated diene formation (not shown). However, due to high
UV absorbance all further experiments were performed using
LL-CL. Saturable activation of Cp by AscH was observed
(Fig. 1A shows one representative experiment), LL-CL1=2max
vs. [AscH] was ¢tted by a hyperbola and the activation con-
stant, Ka, determined to be 19.1 þ 4.5 WM (Fig. 1B).
Increasing AscH concentration both slightly reduced the lag
phase of oxidation and increased the maximal oxidation rate.
The lag phase at 20 WM AscH was only about one-third of the
lag phase in the absence of the reductant.
We also tested UA, the major water-soluble antioxidant in
human plasma, and found a similar, albeit much weaker acti-
vation (Ka = 59.8 WM; data not shown). Addition of 50 WM
H2O2, in order to check for an e¡ect on the Cu2/Cu redox
cycle, could not activate Cp in LDL oxidation, nor was AscH-
enhanced Cp oxidation inhibited (data not shown).
In order to ensure that it was not release of free copper
from Cp which led to extensive LDL oxidation we also sep-
arated LDL and Cp by a dialysis membrane, which e¡ectively
prevented LDL oxidation even in the presence of elevated
concentrations of AscH (not shown).
3.2. Consumption of AscH and K-tocopherol during
Cp-mediated LDL oxidation
During Cp-mediated LDL oxidation (1.5 WM Cp, 0.1 WM
LDL), AscH was consumed prior to K-tocopherol (Fig. 2A),
within about 60 min. AscH spared K-tocopherol, consistent
with ¢ndings for Cu2-induced LDL oxidation [28]. Loading
of LDL with K-tocopherol did not change the lag phase (not
shown) and the lifetime of K-tocopherol (Fig. 2B), nor was
there an increase in maximal LL-CL intensity observed, indi-
cating that K-tocopherol did not redox-activate Cp (not
shown).
3.3. Activation of Cp by dehydroascorbate (DHA)
Figs. 1 and 2 suggest that maximal activation of Cp by
Fig. 1. Enhancement of Cp-mediated LDL oxidation by AscH.
LDL (0.3 WM) was oxidized in the presence of 2.25 WM Cp and the
progress of oxidation monitored by LL-CL. A: One representative
series of experiments with AscH = 0^100 WM. B: A plot of the
square root of (LL-CLmax; 20ÿ100 WM AscH3LL-CLmax; 0 WM AscH) vs.
[AscH] and the ¢tted hyperbola of the saturation kinetics. The
square root of LL-CL corresponds to the oxidation rate.
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AscH occurs only after complete oxidation of AscH by Cp.
Hence, we tested whether DHA, the two-electron oxidation
product of AscH, was able to activate Cp. Fig. 3A shows one
representative experiment and Fig. 3B shows the ¢t of the
hyperbola of a saturation kinetics to the plot LL-CL1=2max vs.
[DHA], similar to Fig. 1. From this plot, the Ka for DHA was
calculated to be 14.0 þ 2.0 WM, which is even lower than for
AscH, indicating a higher a⁄nity of DHA for the active site
of the LDL oxidase function of Cp.
3.4. Incubation of LDL with 15-LOX
To assess the in£uence of lipid hydroperoxides, 0.3 WM
LDL was incubated for 30 min at 37‡C with increasing con-
centrations of 15-LOX, in the presence of 1 mM Ca2, 50 WM
AscH and 300 WM UA, to better approach the physiological
situation and meet the requirements of 15-LOX for binding to
LDL (Fig. 4). While the maximal oxidation rate remained
unchanged at increasing LOX concentrations, the initial oxi-
dation rate increased concentration-dependently.
4. Discussion
Based on the results given above a mechanism for Cp-medi-
ated LDL oxidation in the presence of water-soluble reduc-
tants is proposed. The redox-active entity is the labile Cu2
(Cp-Cu2), which has been described by Ehrenwald et al. [7].
For oxidation of LDL, intact Cp must bind directly to the
lipoprotein.
4.1. Water-soluble antioxidants as activators of Cp-mediated
LDL oxidation
Water-soluble antioxidants which are present in human
plasma in substantial concentrations, e.g. AscH (50^100
WM) or DHA (and UA, 300^400 WM), can act as enhancers
Fig. 2. Consumption of AscH and K-tocopherol during Cp-mediated
LDL oxidation. A: Native LDL (0.1 WM) was incubated with 1.6
WM Cp and 100 WM AscH and aliquots of the oxidation mixture
were used to assay for AscH and K-tocopherol. B: Assay conditions
as in A, except that instead of native LDL, LDL loaded with K-to-
copherol was used.
Fig. 3. Enhancement of Cp-mediated LDL oxidation by DHA.
LDL (0.3 WM) was oxidized in the presence of 2.25 WM Cp and the
progress of oxidation monitored by LL-CL. A: One representative
series of experiments with DHA = 0^100 WM. B: A plot of the
square root of (LL-CLmax; 5ÿ200 WM DHA3LL-CLmax; 0 WM DHA) vs.
[DHA] and the ¢tted hyperbola of the saturation kinetics. The
square root of LL-CL corresponds to the oxidation rate.
FEBS 25036 6-7-01
S. Feichtenhofer et al./FEBS Letters 501 (2001) 42^4644
of lipid peroxidation by Cp, instead of exerting their ‘tradi-
tional’ role in prevention of LDL oxidation. This is even more
remarkable in light of the previous ¢nding that AscH is able
to prevent prooxidant e¡ects which might otherwise occur in
the presence of reductants during metal-catalyzed LDL oxi-
dation [17].
Lipid-soluble antioxidants, namely K-tocopherol, were not
able to enhance Cp-mediated LDL oxidation, even at elevated
concentrations, i.e. after loading of LDL with the antioxidant.
In the case of LDL oxidation mediated by free Cu2, redox
activation by K-tocopherol has been shown to be the trigger
for oxidation, in the absence of lipid hydroperoxides [27,29].
However, the time course of antioxidant consumption indi-
cates that AscH is directly oxidized by Cp, protecting K-toco-
pherol in LDL as long as it is not fully consumed. The strong
activation of Cp-mediated oxidation clearly occurs after the
consumption of AscH which indicates that not AscH, but an
oxidation product may be the true activator.
4.2. DHA activates Cp
Using DHA instead of AscH in the oxidation assays, an
even stronger activation of Cp ensued, suggesting that it may
actually be DHA (or its hydrolysis products, e.g. 2,3-diketo-
gulonic acid) which is responsible for activation. This is cor-
roborated by its Ka value, which is actually even lower than
the Ka for AscH. DHA has been shown previously to become
prooxidant in LDL oxidation once the endogenous K-toco-
pherol content of LDL is exhausted [17,30,31]. Hence, it ap-
pears that the AscH oxidase activity of Cp ¢rst depletes AscH
but in turn provides DHA as another powerful reductant to
the prooxidant copper.
4.3. Saturable activation of Cp by reductants
The observation that di¡erent reductants show a saturable
e¡ect on LDL oxidation by Cp and lead to di¡erent Ka values
(and also to di¡erent maximal rates: LL-CLmax of UA is only
30% that of AscH and DHA (not shown)) indicates an quasi-
enzymatic mechanism, where the reductants act as cosub-
strates. Moreover, the reductive step apparently occurs exclu-
sively from the aqueous side of the bound enzyme, because
lipid-soluble reductants such as K-tocopherol are not able to
activate Cp, either in the absence or in the presence of water-
soluble reductants (Fig. 2). To complete a prooxidant redox
cycle of the Cu2 responsible for LDL oxidase activity [12],
there must be a reoxidation step after reduction. Addition of
H2O2 proved ine¡ective in this, neither enhancing Cp-medi-
ated LDL oxidation nor inhibiting it, which might have been
the case if it competed e.g. with lipid hydroperoxides. This
points to a separation of the oxidation and reduction reac-
tions of Cp in such a way that reduction occurs from the
aqueous phase exclusively, and reoxidation of the Cu takes
place from the lipid phase ^ which is also evident from load-
ing of LDL with lipid hydroperoxides using 15-LOX (Fig. 4).
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